Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.
Moreau, R.J., Skepper, C.K., Appleton, B.A., Blechschmidt, A., Balibar, C.J., Benton, B.M., Drumm, J.E., Feng, B.Y., Geng, M., Li, C., Lindvall, M.K., Lingel, A., Lu, Y., Mamo, M., Mergo, W., Polyakov, V., Smith, T.M., Takeoka, K., Uehara, K., Wang, L., Wei, J.R., Weiss, A.H., Xie, L., Xu, W., Zhang, Q., de Vicente, J.(2018) J Med Chem 61: 3309-3324
- PubMed: 29498517 
- DOI: 10.1021/acs.jmedchem.7b01691
- Primary Citation of Related Structures:  
6CCK, 6CCL, 6CCM, 6CCN, 6CCO, 6CCQ, 6CCS - PubMed Abstract: 
The discovery and development of new antibiotics capable of curing infections due to multidrug-resistant and pandrug-resistant Gram-negative bacteria are a major challenge with fundamental importance to our global healthcare system. Part of our broad program at Novartis to address this urgent, unmet need includes the search for new agents that inhibit novel bacterial targets ...